As Biotechnology businesses, Chimerix Inc. (NASDAQ:CMRX) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ), are affected by compare. This especially applies to their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chimerix Inc.	7.22M	18.98	69.47M	-1.55	0.00
Jazz Pharmaceuticals plc	1.89B	4.14	447.10M	5.93	22.69

We can see in table 1 the earnings per share, top-line revenue and valuation of Chimerix Inc. and Jazz Pharmaceuticals plc.

Profitability

Table 2 shows Chimerix Inc. and Jazz Pharmaceuticals plc’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Chimerix Inc.	-962.19%	-36.5%	-34.7%
Jazz Pharmaceuticals plc	23.66%	15.2%	8.2%

Volatility & Risk

Chimerix Inc. has a 1.36 beta, while its volatility is 36.00% which is more volatile than Standard & Poor’s 500. Jazz Pharmaceuticals plc has a 1.23 beta and it is 23.00% more volatile than Standard & Poor’s 500.

Liquidity

19.9 and 19.9 are the respective Current Ratio and a Quick Ratio of Chimerix Inc. Its rival Jazz Pharmaceuticals plc’s Current and Quick Ratios are 4.3 and 4.2 respectively. Chimerix Inc. has a better chance of clearing its pay short and long-term debts than Jazz Pharmaceuticals plc.

Analyst Ratings

Recommendations and Ratings for Chimerix Inc. and Jazz Pharmaceuticals plc can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Chimerix Inc.	0	3	1	2.25
Jazz Pharmaceuticals plc	0	3	8	2.73

The upside potential is 30.11% for Chimerix Inc. with average price target of $3.5. On the other hand, Jazz Pharmaceuticals plc’s potential upside is 25.44% and its average price target is $172. Based on the data given earlier, Chimerix Inc. is looking more favorable than Jazz Pharmaceuticals plc, analysts belief.

Institutional and Insider Ownership

The shares of both Chimerix Inc. and Jazz Pharmaceuticals plc are owned by institutional investors at 81% and 90.8% respectively. Insiders owned roughly 1.4% of Chimerix Inc.’s shares. On the other hand, insiders owned about 2.5% of Jazz Pharmaceuticals plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Chimerix Inc.	16.16%	-1.29%	-33.53%	-45.11%	-52.97%	-10.51%
Jazz Pharmaceuticals plc	6.52%	6.82%	-8.16%	-21.57%	-4.4%	8.49%

For the past year Chimerix Inc. had bearish trend while Jazz Pharmaceuticals plc had bullish trend.

Summary

Jazz Pharmaceuticals plc beats on 10 of the 13 factors Chimerix Inc.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with ParkinsonÂ’s disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.